FibroGen, Inc. (FGEN)

Market Cap	113.59M
Revenue (ttm)	147.75M
Net Income (ttm)	-284.23M
Shares Out	98.77M
EPS (ttm)	-2.92
PE Ratio	n/a
Forward PE	61.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,310,555
Open	1.160
Previous Close	1.170
Day's Range	1.050 - 1.180
52-Week Range	0.333 - 20.440
Beta	0.74
Analysts	Sell
Price Target	5.00 (+334.78%)
Earnings Date	May 6, 2024

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 14, 2014
• Employees: 486
• Stock Exchange: NASDAQ
• Ticker Symbol: FGEN

Financial Performance

In 2023, FibroGen's revenue was $147.75 million, an increase of 4.99% compared to the previous year's $140.73 million. Losses were -$284.23 million, -3.21% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for FGEN stock is "Sell." The 12-month stock price forecast is $5.0, which is an increase of 334.78% from the latest price.

Price Target

$5.0

(334.78% upside)

Analyst Consensus: Sell